PDF
NACI: Updated recommendations on the use of COVID-19 vaccines in children 5 to 11 years of age
Organization: Public Health Agency of Canada (PHAC)Published: 2022
"The Pfizer-BioNTech Comirnaty COVID-19 vaccine in Canada is approved for use as a 3-dose primary series in individuals who are immunocompromised. As per the product monograph (for both 10 mcg and 30 mcg doses), persons who are immunocompromised, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the vaccine and in these individuals, a third dose may be considered as part of the primary series.
NACI has reviewed the evolving situation and evidence and has updated evidence-informed recommendations on the use of COVID-19 vaccines in pediatric populations." - NACI: Updated recommendations on the use of COVID-19 vaccines in children 5 to 11 years of age
Additional Authors: Matthew C. Tunis, Robert Pless, Marina Salvadori, Bryna Warshawsky, Adrienne Stevens, Shainoor J. Ismail, Robyn Harrison, Beate Sander, and Shelly Deeks
Product Type: Guide
Category:
Vaccine Safety and Development,Vaccine Safety,Sub Topics: Vaccine Safety and Development,Monitoring and Surveillance,Outbreaks and Pandemics,COVID-19,Program Planning and Delivery,Program Delivery and Evaluation,Clinics,Vaccine Management,Allocation and Distribution Vaccine Safety and DevelopmentVaccine Safety
Sub Topics: Vaccine Safety and Development
Monitoring and Surveillance
Outbreaks and Pandemics
COVID-19
Program Planning and Delivery
Program Delivery and Evaluation
Clinics
Vaccine Management
Allocation and Distribution
Population: School-aged Children
High Risk Children
Region: National
Link
AudioResource Rating Breakdown
Ratings submitted by CANVax users for this resource are tallied to provide an average resource rating per category.
0 Comments
Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.
All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.
You must login or register before you can submit a comment.